Sign inJoin waitlistJoin the waitlist

Hong Song

Assistant Professor of Radiology · Stanford Health Care

Credentials: · · · · ·

History

Stanford Health Care
Present
Stanford Health Care
Present

Nuclear Radiology
Stanford Health Care
2022–2023
Radiology-Diagnostic
Stanford Health Care
2018–2022
Stanford University
2017–2022
Nuclear Medicine
Stanford Health Care
2016–2019
Internal Medicine
Tulane University School of Medicine
2014–2017
Tulane University
Tulane University School of Medicine
2012–2016

Research

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy
Journal of Nuclear Medicine · 2010 · 426 citations
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y
Cancer Research · 2009 · First of 8 authors · 122 citations
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry
Journal of Nuclear Medicine · 2007 · 110 citations

Andrei Iagaru
15 papers
Farshad Moradi
11 papers
Guido Davidzon
11 papers
Richard Wahl
8 papers
Kip Guja
6 papers · 6 as a fellow
Benjamin Franc
5 papers
Sandy Srinivas
4 papers
Ali Khaki
3 papers
Andreas Loening
3 papers
Caitlyn Harrison
3 papers · 3 as a resident
CB
Colin Bergstrom
3 papers
Jagruti Shah
3 papers

Clinical trials

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2032
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Site PI · Recruiting · Phase 2, Phase 3
Novartis Pharmaceuticals
2025–2033
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Site PI · Recruiting · Phase 1
Novartis Pharmaceuticals
2024–2028
Study With [225Ac]Ac-FL-020 in mCRPC Participants
Site PI · Recruiting · Phase 1
Full-Life Technologies UK Limited
2024–2027